A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Idelalisib with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia

Trial Profile

A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Idelalisib with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
  • Indications Lymphoid leukaemia
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 05 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 22 Nov 2016 Planned End Date changed from 31 Aug 2022 to 1 Oct 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top